Proteasome Function & Protein Recycling Explained | Molecular Animation

The proteasome is a large protein complex present in all cells of humans, animals, plants, and fungi, responsible for breaking down damaged or defective proteins into reusable peptide fragments. It consists of a cylindrical 20S core unit where protein breakdown occurs, coupled with 19S regulatory units at one or both ends that recognize proteins marked with ubiquitin chains for degradation. When the proteasome functions correctly, it eliminates damaged proteins to maintain cellular health; however, when its activity decreases, toxic proteins accumulate, leading to neuronal destruction in neurodegenerative diseases such as Alzheimer's and Parkinson's. Research aims to understand how to increase proteasome activity to prevent toxic protein accumulation and potentially treat these diseases.

The ubiquitin-proteasome system normally degrades damaged or misfolded proteins. In neurodegenerative diseases, this system becomes dysfunctional, allowing abnormal proteins to accumulate. In Parkinson's disease, this contributes to Lewy body formation. In Huntington's disease, mutant huntingtin protein accumulates due to impaired degradation. Proteasome dysfunction represents a common mechanism in multiple neurodegenerative diseases.

In ALS models caused by glycine-alanine repeat expansions, toxic protein aggregates recruit massive numbers of proteasomes (40-fold increase) that become functionally trapped. Proteasomes attempt to degrade aggregated proteins but cannot unfold them, resulting in accumulation of proteasomes in substrate-processing states. This trapping mechanism explains why proteasome inhibition worsens ALS pathology—reducing the already overwhelmed proteasome pool impairs clearance of both normal and pathological substrates. The aggregates contain polymorphic ribbon structures with proteasomes inhabiting the material, demonstrating how misfolded proteins disrupt cellular proteostasis networks and contribute to neurodegeneration.

Proteins determine cellular function through their three-dimensional shape. Cells use chaperone proteins to ensure proper folding during synthesis and after stress-induced unfolding. When stress overwhelms chaperone capacity, misfolded proteins aggregate into insoluble fibrils. These aggregates represent quality control failure and are hallmarks of Alzheimer's, Parkinson's, Huntington's, and ALS. The ubiquitin-proteasome system normally degrades damaged proteins, but when impaired, aggregates accumulate. This protein misfolding pathway is central to understanding neurodegenerative disease mechanisms.

Neurodegenerative diseases, such as Alzheimer's and Parkinson's, result from the accumulation of misfolded proteins that overwhelm cellular quality control systems. The ubiquitin-proteasome system (UPS) is the primary cellular mechanism for degrading misfolded proteins, where proteins are tagged with ubiquitin and degraded by the proteasome. When UPS function is impaired, misfolded proteins accumulate, leading to neurodegeneration. A holistic approach to treating these diseases involves understanding the interconnected nature of cellular processes—including protein synthesis, folding, and degradation—and developing therapies that enhance proteasome activity or prevent protein misfolding, rather than targeting single pathways in isolation.

Proteasome inhibitors were developed by designing molecules mimicking natural substrates. Initial compounds like MG132 (three leucines) were converted into boronate derivatives, yielding bortezomib (PS-341), now used by over 700,000 cancer patients worldwide. Bortezomib selectively blocks the chymotrypsin-like site, stabilizing cell cycle regulators and inducing apoptosis through proteotoxic stress. Multiple myeloma cells are particularly vulnerable because they produce abnormal immunoglobulins overwhelming the ubiquitin-proteasome pathway. Blocking this pathway further activates the unfolded protein response and inhibits NF-kappaB signaling, making it highly effective against this disease with over 95% response rates in combination therapy. Approved inhibitors mainly block the chymotrypsin-like site, leaving other proteolytic sites functional at 50-70% normal rates, allowing cells to compensate partially.

Bortezomib (Velcade) was the first drug targeting the ubiquitin-proteasome system, developed through serendipitous screening at NIH. It is a boronic acid derivative that specifically inhibits the chymotrypsin-like active site of the proteasome's beta subunits. Originally designed to treat pregnancy-related nausea (thalidomide), it was found to kill malignant B-cells in multiple myeloma. The drug exploits the unfolded protein response: malignant plasma cells secrete excessive immunoglobulins, some misfolded and degraded by ER-associated degradation. When proteasome inhibition blocks degradation, misfolded proteins accumulate, triggering apoptosis. Bortezomib dramatically improves outcomes in multiple myeloma, reducing tumor burden from 41% to less than 1% in bone marrow.

Bortezomib is a boron-containing compound that covalently binds to proteasomes and inhibits proteolytic activity. The proteasome is a complex proteolytic enzyme responsible for degradation of intracellular signaling proteins involved in cell cycle control, apoptosis, and survival responses. Mechanism: NF-kappa-B mediated signaling is interrupted by bortezomib. Under stress (hypoxia, cytotoxic drugs, DNA breaks), proteasome cleaves the Ikappa-B/NF-kappa-B complex, releasing NF-kappa-B which promotes anti-apoptosis and cell proliferation. Bortezomib prevents this cleavage, inhibiting NF-kappa-B activity and promoting apoptosis while decreasing cell proliferation. It also increases pro-apoptotic proteins. Route: IV infusion or subcutaneous injection. Uses: multiple myeloma and refractory mantle cell lymphoma. Adverse effects: peripheral neuropathy, diarrhea, fatigue, depression, thrombocytopenia.

Proteasome inhibitors (bortezomib, carfilzomib, ixazomib) represent a cornerstone of modern multiple myeloma treatment, approved for newly diagnosed, relapsed, and refractory disease. These agents block proteasome function, disrupting cellular regulatory signals and inducing apoptosis in cancer cells while sparing normal cells. Bortezomib, the oldest agent, commonly causes thrombocytopenia, infections, and peripheral neuropathy, now administered subcutaneously to reduce neurotoxicity. Carfilzomib, an irreversible inhibitor given once/twice weekly, requires pre-dose blood counts and carries thrombotic and cardiac risks requiring baseline cardiac assessment. Ixazomib, an oral agent given weekly on empty stomach, offers convenient administration but requires viral prophylaxis and monitoring for cyclic thrombocytopenia. All proteasome inhibitors necessitate routine CBC monitoring and dose adjustments for renal/hepatic impairment.

Proteasome inhibitors are a class of drugs that block the proteasome, a cellular recycling system responsible for breaking down excess proteins; by inhibiting this process, these drugs cause toxic protein accumulation in myeloma cells, leading to cell death, and newer generations (carfilzomib and ixazomib) offer improved efficacy with fewer side effects, particularly reduced peripheral neuropathy, compared to the first-generation drug bortezomib.

Autophagy differs fundamentally from the ubiquitin-proteasome system in its approach to protein degradation. While the ubiquitin-proteasome system recognizes and degrades specific target proteins through sophisticated recognition mechanisms, autophagy provides a bulk degradation pathway that can eliminate entire cellular components including organelles. This makes autophagy particularly important for eliminating damaged or excessive cellular material that cannot be targeted by specific degradation systems.

Autophagy and the ubiquitin-proteasome system represent two major cellular degradation pathways that work together and regulate each other. Autophagy degrades damaged organelles and protein aggregates through autophagosome-lysosome fusion, while the ubiquitin-proteasome system degrades misfolded proteins via proteasomal degradation. Surprisingly, ubiquitination also marks proteins for autophagy, with p62 adaptors recognizing ubiquitin and LC3 to deliver cargo to autophagosomes. These pathways cross-regulate each other: when autophagy should be off, the proteasome degrades autophagy proteins; when autophagy should be on, autophagy proteins inhibit specific ubiquitin ligases. AMBRA1 serves as a central regulator, interacting with both CUL4 and CUL5 ubiquitin ligases to coordinate degradation responses based on cellular conditions.

The ubiquitin-proteasome system provides precise, selective degradation of specific target proteins, while lysosomal degradation causes bulk, non-selective degradation of cellular components. In UPS, ubiquitin is specifically attached to target proteins before degradation, making it highly selective for damaged, misfolded, or unnecessary proteins. In contrast, lysosomes degrade various materials including long-lived proteins, organelles, and extracellular components without specific targeting. Lysosomes contain digestive enzymes (proteases, lipases) that work optimally at acidic pH and are responsible for breaking down cellular waste. Proteins reach lysosomes through endocytosis (external materials), phagocytosis (large particles like bacteria), and autophagy (cellular components enclosed in vesicles).

Cells employ two major protein degradation pathways: the lysosomal pathway and the ubiquitin-proteasome system (UPS). The lysosome degrades proteins non-selectively through endocytosis or autophagy in acidic compartments. The UPS performs selective degradation of ubiquitin-marked proteins, serving quality control and cell state-dependent removal. The UPS operates through a cascade of E1, E2, and E3 enzymes: E1 activates ubiquitin, E2 transfers it, and E3 ligases bring substrates close for ubiquitination. Over 600 human E3 ligases exist, with most involved in degradation. The 26S proteasome contains a regulatory cap with ubiquitin-binding domains and ATPases, plus a barrel-shaped 20S core where proteases cleave peptides.

The ubiquitin-proteasome system (UPS) and autophagy are two major catabolic pathways that interact bidirectionally: UPS malfunction activates autophagy through P62-mediated mechanisms involving TFEB nuclear translocation, while autophagy impairment reciprocally compromises UPS function, creating a complex regulatory network essential for protein quality control and cardiac health.